|
|
| Volume 17 • Issue 10 |
May 17, 2017 |
 |
|
|
 |
| |
 |
|
|
IMPORTANT INFORMATION
TEMPORARY BACKORDER OF SUPREFACT®
INJECTABLE SOLUTION 1 MG/ML (BUSERELIN ACETATE)
Sanofi-aventis Canada Inc. would like to inform you that Suprefact® injectable solution (buserelin acetate) is on temporary backorder due to manufacturing delays.
Read more
|
|
|
|
| |
 |
|
|
PRODUCT AVAILABILITY: EDARBI AND EDARBYCLOR
– NOTICE TO PHARMACISTS
Read more
|
|
 |
| |
 |
|
|
PrVIBERZITM (ELUXADOLINE) IS NOW AVAILABLE IN CANADA
Allergan Pharma Co. (“Allergan”) is pleased to announce the Canadian launch of VIBERZITM.
Read more
|
|
|
|
| |
 |
|
|
INTRODUCING LIXIANA®
Servier Canada Inc. is pleased to announce that LIXIANA® (edoxaban)
is now available.
Read more
|
|
 |
| |
 |
|
|
MURO 128® 5% OINTMENT BACK IN STOCK
Muro 128® Sodium chloride Ophthalmic Ointment USP, Sterile 5% Hypertonic, providing nighttime relief from corneal edema, is BACK IN STOCK!
Read more
|
|
 |
|
|
